Mereo BioPharma licenses alvelestat to Sentynl in $475m-plus US deal
Mereo BioPharma has entered an option and licence agreement with Sentynl Therapeutics, granting the US-based rare-disease company the exclusive right to commercialise alvelestat in the United States for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo retains development leadership and commercial rights in all other markets.
Under the agreement, Sentynl, a wholly-owned subsidiary of Indian conglomerate Zydus Lifesciences, will pay Mereo a non-refundable upfront option fee. Should it exercise the option, Mereo would receive $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestone payments, and double-digit tiered royalties on US net sales. Sentynl also receives global manufacturing rights to alvelestat as part of the deal. A Phase 3 programme could begin as early as the first quarter of 2027, with the two companies expected to use the option period to align on study design.
The asset and indication
Alvelestat is a once-daily oral small molecule that selectively inhibits neutrophil elastase, an enzyme central to lung tissue destruction in AATD-LD. The disease arises from a genetic deficiency of the alpha-1 antitrypsin protein, leaving the lungs vulnerable to progressive, potentially fatal emphysema. An estimated 50,000 to 80,000 people in the United States carry the Pi*ZZ variant associated with severe lung involvement.
The current standard of care for AATD-LD relies primarily on augmentation therapy, an intravenous infusion of purified alpha-1 antitrypsin protein typically administered weekly. Oral alternatives do not exist in this indication. Alvelestat has received Orphan Drug Designation from both the FDA and the European Commission, and holds FDA Fast Track designation, reflecting the agency's view that it addresses a serious condition with an unmet need. Mereo says the safety and tolerability profile of the molecule has been established across clinical trials in more than 1,000 patients with respiratory conditions, including two Phase 2 studies in AATD-LD that the company describes as showing positive efficacy data.
Denise Scots-Knight, chief executive of Mereo, said the company had been preparing alvelestat for a global Phase 3 study and viewed Sentynl's rare-disease commercial infrastructure as complementary to that effort. Sentynl chief executive Matt Heck noted that AATD-LD represented an opportunity to reach a broader rare-disease population than Sentynl's existing ultra-rare focus, while still fitting its strategic remit.
Market context and competitive landscape
AATD-LD has attracted modest but growing industry attention. The dominant augmentation therapy market is served by a small number of plasma-derived products. A shift to an oral, small-molecule mechanism-based approach would represent a meaningful change in treatment paradigm, if clinical and regulatory success follows. Several investigational programmes targeting neutrophil elastase or related inflammatory pathways in chronic respiratory disease are in earlier stages of development, though none has yet reached late-stage trials in AATD specifically.
For Mereo, the deal follows a pattern of structuring geographically split partnerships across its pipeline. Its osteogenesis imperfecta candidate setrusumab is being developed globally by Ultragenyx, with Mereo holding EU and UK commercial rights; a similar model applies here, with Mereo leading Phase 3 and retaining ex-US rights to alvelestat. That strategy limits Mereo's cash burn on commercialisation while preserving upside in the larger European and UK markets.
The size of the potential milestone package, $435 million on top of the $40 million on option exercise, reflects the commercial ambition attached to a would-be first oral therapy in a defined rare-disease population. Whether that ambition is realised will depend on Phase 3 design, enrolment timelines, and the regulatory read-across from existing augmentation therapy precedents at the FDA.